An update from Abingdon Health PLC ( (GB:ABDX) ) is now available.
Abingdon Health PLC has announced the extension of its distribution agreement with Salignostics to launch Salistick™, a saliva-based pregnancy test, in Germany and other European markets. Following its successful launch in the UK, Salistick™ will be available in major German retailers, with an initial purchase order of 70,000 tests. This expansion is expected to enhance Abingdon Health’s market presence in Europe and provide consumers with a novel, convenient pregnancy testing option.
More about Abingdon Health PLC
Abingdon Health PLC is a leading med-tech contract service provider offering lateral flow product development, regulatory support, technology transfer, and manufacturing services. The company serves an international customer base, focusing on areas such as infectious disease, clinical testing, animal health, and environmental testing. Abingdon Health also provides regulatory services and offers a range of self-tests through its Abingdon Simply Test e-commerce platform.
YTD Price Performance: -12.90%
Average Trading Volume: 116,209
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.07M
For an in-depth examination of ABDX stock, go to TipRanks’ Stock Analysis page.